These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


380 related items for PubMed ID: 12545140

  • 1. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
    Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.
    Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS, Huitema AD, Yalvaç Z, Prins JM, Mulder JW, Meenhorst PL, Beijnen JH.
    Clin Pharmacokinet; 2005 Jan; 44(8):849-61. PubMed ID: 16029069
    [Abstract] [Full Text] [Related]

  • 3. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD, 2NN Study Group.
    Antivir Ther; 2005 Jan; 10(1):145-55. PubMed ID: 15751772
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
    Csajka C, Marzolini C, Fattinger K, Décosterd LA, Telenti A, Biollaz J, Buclin T.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3226-32. PubMed ID: 15328077
    [Abstract] [Full Text] [Related]

  • 5. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
    Pereira SA, Branco T, Caixas U, Côrte-Real RM, Germano I, Lampreia F, Monteiro EC.
    Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
    [Abstract] [Full Text] [Related]

  • 6. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, Beijnen JH, Lange JM, Reiss P, Hoetelmans RM.
    J Infect Dis; 2001 Jul 01; 184(1):37-42. PubMed ID: 11398107
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S, Breilh D, Pellegrin I, Lavit M, Camou F, Caubet O, Fleury H, Saux MC, Pellegrin JL.
    J Antimicrob Chemother; 2006 Nov 01; 58(5):1090-3. PubMed ID: 16921181
    [Abstract] [Full Text] [Related]

  • 10. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
    Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T.
    AIDS; 2001 Jan 05; 15(1):71-5. PubMed ID: 11192870
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
    Langmann P, Weissbrich B, Desch S, Väth T, Schirmer D, Zilly M, Klinker H.
    Eur J Med Res; 2002 Jul 24; 7(7):309-14. PubMed ID: 12176680
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.
    Antivir Ther; 2013 Jul 24; 18(1):105-13. PubMed ID: 23043067
    [Abstract] [Full Text] [Related]

  • 15. [Evidence-based therapeutic drug monitoring for efavirenz].
    Solas C, Gagnieu MC, roupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.
    Therapie; 2011 Jul 24; 66(3):197-205. PubMed ID: 21819803
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
    Poeta J, Linden R, Antunes MV, Real L, Menezes AM, Ribeiro JP, Sprinz E.
    J Antimicrob Chemother; 2011 Nov 24; 66(11):2601-4. PubMed ID: 21890538
    [Abstract] [Full Text] [Related]

  • 19. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
    Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R.
    Br J Clin Pharmacol; 2006 Feb 24; 61(2):148-54. PubMed ID: 16433869
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 19.